SCOPE of Pain: Safe and Competent Opioid Prescribing Education

Format
Patient Case Study

Time to Complete
3 hours

Released
March 1, 2013

Expires
February 28, 2016

Date of Most Recent Review
March 1, 2014

Maximum Credits
3.00 / AMA PRA Category 1 Credit(s)™
3.00 / AAFP Prescribed Credits
3.00 / CE for Nurses

Accredited Provider
BOSTON UNIVERSITY

Disclosure of Support
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see http://ce.er-la-opioidrems.com/CEU/remf/pdf/List_of_RPC_Companies.pdf for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

Needs Addressed Statement
Healthcare practitioners who prescribe ER/LA opioid analgesics to treat chronic pain are in a key position to balance the benefits and risks of Chronic Opioid Treatment (COT). The importance of education for HCPs cannot be overstated as, according to a 2011 report by the Institute of Medicine, the social and economic burden of pain nationwide is staggering. The IOM Report found that the annual health economic impact of pain represents a $560 to $635 billion burden to the U.S. The escalation of opioid prescribing and the corresponding increase in opioid misuse (including abuse, addiction, overdose, and diversion) have been well documented by both regulatory agencies and the lay press. According to SAMHSA’s 2010 National Survey of Drug Use and Health report, among the U.S. population aged 12 or older, nonmedical use of prescription pain relievers was the second most prevalent type of illicit drug use after marijuana use. In addition, mortality rates from unintentional overdose of opioids are increasing dramatically. Despite these concerns, according to the National Institute on Drug Abuse, opioid pain
medicines are safe and usually do not cause addiction when managed well medically and taken as prescribed. However, HCPs struggle with the need to assist their patients with adequate management of chronic pain while confronting the risks associated with opioid prescribing.

References


Intended Audience
Physicians, nurse practitioners, registered nurses, nurses, physician assistants, dentists, and pharmacists

Educational Objectives

Module 1
Assessing Chronic Pain and Opioid Misuse Risk
At the conclusion of this activity, participants will be able to:
- Discuss prevalence of chronic pain in the US
- Discuss prevalence of the use and misuse of opioid analgesics
- Describe the pharmacology, efficacy and safety of opioid analgesics
- Describe the components of a thorough opioid misuse risk assessment for a potential candidate for chronic opioid therapy

Module 2
Initiating Opioid Therapy Safely
At the conclusion of this activity, participants will be able to:
- Describe universal precautions and their role in chronic opioid therapy
- Describe monitoring and documentation strategies for chronic opioid therapy
- Describe initiating opioid therapy
- Apply counseling and communication strategies to ensure appropriate and safe use of opioid medications

Module 3
Assessing and Managing Aberrant Medication Taking Behavior
At the conclusion of this activity, participants will be able to:
- Assess differential diagnosis for aberrant medication taking behavior - Pain relief vs drug seeking
- Assess lack of benefit, increased risk and/or harm
- Determine whether to continue, change or discontinue opioid therapy
- If changing opioids, determine how to rotate opioids
- If discontinuing opioids, determine whether and how to taper opioids
Disclosure Policy
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices occurs.

Faculty
Daniel P. Alford, MD, MPH, FACP, FASAM
Course Director
Associate Professor of Medicine and
Assistant Dean of Continuing Medical Education
Boston University School of Medicine
Program Director of the Addiction Medicine Fellowship
Boston Medical Center
Boston, Massachusetts

Dr. Alford has nothing to disclose with regards to commercial support. He does discuss the off-label use of sublingual buprenorphine to treat pain. Buprenorphine has been FDA approved for addiction treatment but not pain treatment.

Seddon Savage, MD, MS, FASAM
Adjunct Associate Professor of Anesthesiology
Dartmouth Medical School
Director, Dartmouth Center on Addiction Recovery and Education
Dartmouth College and Dartmouth Medical School
Hanover, New Hampshire

Dr. Savage has nothing to disclose with regards to commercial support. She does not discuss unlabeled/investigational uses of a commercial product.

Catherine Silva, MD
Director of Adult Medicine
FACULTY
Online CME & CE courses | myCME | Continuing Medical Education - myCME.com
East Boston Neighborhood Health Center
Boston, Massachusetts

Dr. Silva discloses that she is a stockholder in Merck & Co., Inc. owning less than 100 shares. She does not discuss unlabeled/investigational uses of a commercial product.

Lynn Webster, MD, FACPM, FASAM
Chief Medical Director
CRI-Lifetree
President-Elect
American Academy of Pain Medicine
Salt Lake City, UT

Dr. Webster is a consultant for Covidien Mallinckrodt, Medtronic, Nektar Therapeutics, and Salix Pharmaceuticals. He does not discuss unlabeled/investigational uses of a commercial product.

Program Moderator
Judie Yuill, Fill-in News Anchor and Host, WGBH Boston and Exclusive Female Voice, Parlance Corporation, has nothing to disclose with regards to commercial support.
Planning Committee
Patti-Ann Collins, DNP, MSN/MBA, RN, Lead Nurse Planner, BUSM
Ilana Hardesty, Program Operations Manager, BUSM
Colleen Labelle, RN, Nursing Course Advisor, BUSM
Jeffrey Markuns, MD, EdM, independent reviewer
Stephen A. Wyatt, DO, independent reviewer
Jason Worcester, MD, independent reviewer

Planning committee members have nothing to disclose with regards to commercial support.

Advisory Committee
Norman Kahn, MD, Executive Vice-President and CEO, Council of Medical Specialty Societies
Stancel Riley, MD, Lecturer on Surgery, Harvard Medical School and Research Associate, Department of Health Policy Management, Harvard School of Public Health
Lisa Robin, Chief Advocacy Officer, Federation of State Medical Boards

Advisory committee members have nothing to disclose with regards to commercial support.

<table>
<thead>
<tr>
<th>Credit</th>
<th>Type</th>
<th>Accreditation Statement</th>
<th>Designation Statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.00</td>
<td>AMA PRA Category 1 Credit(s)</td>
<td>Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</td>
<td>Boston University School of Medicine designates this enduring material CME activity for a maximum of 3.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.</td>
</tr>
<tr>
<td>3.00</td>
<td>CE for Nurses</td>
<td>Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.</td>
<td>CNE Contact Hours: 3.00, all of which is pharmacology credit worthy.</td>
</tr>
</tbody>
</table>
Accreditation Statement
This enduring material activity, SCOPE of Pain: Safe and Competent Opioid Prescribing Education, has been reviewed and is acceptable for up to 3.00 Prescribed credits by the American Academy of Family Physicians. AAFP certification begins March 1, 2013. The term of approval is for one year from this date with the option of yearly renewal. This activity has been approved from March 1, 2014 - February 28, 2016. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclaimer
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.

Non-Endorsement of Products
Continuing Nursing Education Provider Unit, Boston University School of Medicine’s provider status refers only to continuing nursing education activities and does not imply that there is real or implied endorsement by Continuing Nursing Education Provider Unit, Boston University School of Medicine or ANCC of any product, service, or company referred to in this activity nor of any company subsidizing costs related to the activity.

Instructions
Risk Management and Pain Management Credits
Boston University School of Medicine designates this activity for three hours of risk management study and opioid education.

This program meets the criteria of the Massachusetts Board of Registration in Medicine for 3 hours of risk management study and opioid education.

Please check with your licensing board to determine if this activity will fulfill other state-specific requirements.

In order to receive credit, participants must view the content of each module and complete the post-test and evaluation for all three of the modules. Participants who receive a grade of 70% or greater on all
three post-tests will receive credit. **All three modules must be completed in order to earn your online certificate of credit** of 3.00 AMA PRA Category 1 Credit(s)™, 3.00 AAFP Prescribed credits, or 3.00 nursing contact hours. There will also be an online follow-up survey that will be distributed two months after completion of the program in order to further measure participants' changes in knowledge and behavior.